New understanding of B cell mutation strategies could have implications for vaccines
A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a ...
Healio10d
Two more people potentially cured of HIV
Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...
eLife10d
Parallel HIV-1 fitness landscapes shape viral dynamics in humans and macaques that develop broadly neutralizing antibodies
An effective HIV-1 vaccine must therefore elicit antibodies that can neutralize many variants of the virus. While broadly neutralizing antibodies (bnAbs) have been isolated from HIV-1 infected ...
Medscape4d
Two-Drug HIV Regimen Matches Standard of Care Therapy in Absence of Drug Resistance Testing
Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...
Technology Networks2d
New Insights Into B Cell Mutations Could Improve Vaccine Strategies
Successful high-affinity B cells can proliferate under special conditions that reduce the risk of mutation. Capturing this ...
GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
News-Medical.Net on MSN1d
Study reveals how B cells safeguard high-affinity antibodies
A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a vaccine or pathogen, B cells scramble to refine their defenses, rapidly mutating ...
Mirage News1d
Second Patient Achieves Sustained HIV Remission
Emory University's pioneering work with a class of small molecules known as JAK (janus kinase) inhibitors continues to show how HIV might be cured ...
Sciencenorway7d
Norwegian man likely cured of HIV
A Norwegian man has been free of the virus for nearly two and a half years following treatment and is likely cured of HIV.
Fierce Biotech8d
GSK posts data on HIV assets vying for roles in 6-month combo
GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...
BioSpace8d
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...